#China #Xi'an #Tianlong #Blood Safety #AIDS Day

Enhancing Blood Transfusion Safety: Tianlong's Commitment on World AIDS Day 2025

On November 28, 2025, Tianlong Science and Technology reinforced its dedication to global transfusion safety by unveiling an integrated nucleic acid testing solution on World AIDS Day. This initiative targets the critical need for early detection of blood-borne infections, particularly those that could be transmitted through transfusions, such as HIV.

Pioneering Blood Safety Solutions

Tianlong has introduced an innovative approach that combines advanced automation with high-sensitivity NAT reagents, tailored to detect infections even at low viral loads. This technology not only enhances the accuracy of blood screenings but also promotes the safety of blood supplies for patients who rely on transfusions. By improving early detection capabilities, Tianlong is playing a vital role in reducing the risk of transfusion-transmitted infections.

The Importance of Early Detection

The necessity of ensuring blood safety has never been more urgent. Blood transfusion is one of the most effective defenses against infections transmitted through medical procedures. Tianlong's state-of-the-art automated solution, the Aurora PANA X6, is specifically engineered to facilitate large-scale blood screening. It enables laboratories to detect critical viruses such as HBV, HCV, HIV-1, and HIV-2 during the early stages of infection, effectively supporting global public health initiatives.

The Aurora PANA X6 is capable of processing up to 576 samples in a single analysis and can handle 1,152 samples daily. This capacity not only meets the high-volume demands of blood screening but does so with consistent, contamination-free operations. The automation of the sample loading and processing workflows ensures operational efficiency and minimized human error, essential factors in laboratory settings.

Features of the Aurora PANA X6

• - Fully Automated Workflow: The system offers a streamlined process that integrates sample loading, tube identification, sealing, and PCR setup while ensuring high levels of operational safety.
• - High-Throughput Processing: With its capability to perform large batch tests, the Aurora PANA X6 meets the increasing needs for efficient blood screening.
• - Direct Grouping and Screening Options: The system supports both individual and grouped testing (up to six samples per analysis), enabling laboratories to find an optimal balance between efficiency and sensitivity.
• - Enhanced Biosecurity Measures: Equipped with HEPA filtration, UV disinfection, and controlled airflow, the system maintains strict biosecurity, which is crucial in handling blood samples.

NAT Reagents for Accurate Viral Detection

Complementing Tianlong's automation, the high-sensitivity NAT reagents provide qualitative real-time PCR capabilities. These reagents are designed to accurately detect HBV, HCV, HIV-1, and HIV-2 even when viral loads are low. This early detection capability is crucial for timely intervention and effective risk reduction, ensuring safer blood transfusion practices.

A Shared Commitment to Safer Transfusions

Li Ming, CEO of Tianlong, emphasized the importance of their mission on World AIDS Day, stating, "Every safe transfusion represents a promise of protection for another human life. Our goal is to provide laboratories with solutions that enhance precision, improve biosecurity, and support global efforts to prevent HIV transmission."

About Tianlong Science and Technology

Founded in 1997, Tianlong Science and Technology is a leader in genetic testing and molecular diagnostics. Alongside our subsidiary, KHB, we offer four key technology platforms: immunodiagnostic, biochemical, molecular diagnostics, and mass spectrometry. Our expertise extends across various sectors, including clinical diagnostics, blood centers, disease control, and food safety.

For more information, visit the official Tianlong website or follow us on our social media channels for updates.